Hee-Jin Jang

6PUBLICATIONS
40CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Apr 10, 2025
Ad-SGE-DKK3 Gene Therapy Overcomes Resistance to Immune Checkpoint Blockade in Pleural Mesothelioma.

Hee-Jin Jang, Meera Patel, Daniel Y Wang

|Dec 05, 2022
A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma.

Hyun-Sung Lee, Hee-Jin Jang, Maheshwari Ramineni

|Aug 22, 2022
Activation of Adaptive and Innate Immune Cells via Localized IL2 Cytokine Factories Eradicates Mesothelioma Tumors.

Amanda M Nash, Samira Aghlara-Fotovat, Bertha Castillio

|Jun 16, 2022
Therapeutic Targeting of Macrophage Plasticity Remodels the Tumor-Immune Microenvironment.

Hee-Jin Jang, Hyun-Sung Lee, Wendong Yu

|May 05, 2018
Clinical and genomic landscape of gastric cancer with a mesenchymal phenotype.

Sang Cheul Oh, Bo Hwa Sohn, Jae-Ho Cheong

|Oct 21, 2017
Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers.

Chan-Young Ock, Jun-Eul Hwang, Bhumsuk Keam

Pageof 1